Topical Antiseptic Formulations for Skin and Soft Tissue Infections.
Thi Phuong Nga HoangMuhammad Usman GhoriBarbara R ConwayPublished in: Pharmaceutics (2021)
Skin and soft tissue infections (SSTIs) are usually acute conditions of inflammatory microbial occupation of the skin layers and underlying soft tissues. SSTIs are one of the most frequent types of infection, typically requiring medical intervention and contribute to morbidity and mortality in both primary care and hospitalised patients. Due to the dramatic rise of antibiotic resistance, antiseptic agents can be potential alternatives for the prevention and treatment of SSTIs. Notably, they are commonly recommended in many global practical guidelines for use in per- and post- operative procedures. A range of antiseptics, including chlorhexidine, triclosan, alcohol, and povidone-iodine, are used and are mainly formulated as traditional, simple dosage forms such as solutions and semi-solids. However, in recent years, there have been studies reporting the potential for nanotechnology in the delivery of antiseptics. In this review, we have collated the scientific literature that focuses on topical antiseptic formulations for prevention and treatment of SSTIs, and have divided findings into traditional and advanced formulations. We conclude that although nanotechnological formulations have demonstrated potential advantages for delivering drugs; nevertheless, there is still scope for traditional formulations and further development of optimised topical formulations to address the rise of antimicrobial resistance.
Keyphrases
- soft tissue
- wound healing
- antimicrobial resistance
- primary care
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- liver failure
- systematic review
- ejection fraction
- newly diagnosed
- human health
- emergency department
- gene expression
- magnetic resonance imaging
- magnetic resonance
- computed tomography
- respiratory failure
- oxidative stress
- microbial community
- clinical practice
- intensive care unit
- hepatitis b virus
- adverse drug
- peritoneal dialysis
- replacement therapy
- electronic health record
- patient reported outcomes